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Systemic lupus erythematosus (SLE) is an 
autoimmune disease characterized by 
autoantibodies directed against self antigens1. Its 
clinical manifestations are extremely variable, and 
its natural history is unpredictable; untreated SLE is 
often progressive and leads to death2. The 
prevalence of SLE has been estimated to be 
between 4 and 250 per 100000 population, being 
more common in urban than in rural areas 3. 
The disease mechanisms of SLE remain 
unknown. Researches suggest that many factors: 
genetic, hormonal and environmental contribute to 
immune dysregulation in lupus1. Investigations 
have recently focused on the normal phenomenon 
of programmed cell death (apoptosis), which is an 
important mechanism by which lymphocytes are 
removed from the site of inflammation 4. 
Dysregulation of apoptosis is associated with the 
pathogenesis of a wide array of diseases: cancer, 
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Background: In systemic lupus erythematosus (SLE), which is the prototype of  
autoimmune diseases, the autoimmune process seems to be antigen driven. 
Apoptosis is responsible for eliminating cells from the immune system that are 
autoreactive, and defects in apoptosis may contribute to autoimmune diseases 
such as SLE and juvenile rheumatoid arthritis (JRA). 
Objective: This work is aimed to study the apoptotic peripheral blood 
lymphocytes in patients with pediatric- onset SLE, to trace its correlations, if 
any, with the disease activity and clinical presentation, and to compare the 
apoptotic process to that in JRA, as an example of another rheumatologic 
disorder. 
Methods: The study was conducted on 32  patients with pediatric- onset SLE; 
their ages ranged between 5 and 25 years (mean + SD = 15.5 + 4.4). In 
addition to various laboratory investigations needed for diagnosis, assessment 
of different system involvement as well as disease activity,  the percentage of 
early circulating apoptotic lymphocytes was measured by flowcytometry  using 
Annexin –V. The results were compared to that of 20 age and sex matched 
clinically healthy children and adolescents as well as 10 JRA patients. 
Results: The percentage of circulating early apoptotic lymphocytes was 
significantly higher in SLE patients (mean ± SD = 7.02 ± 7.29 %)  and JRA 
patients (mean ± SD=5.91± 6.00 %) as compared to healthy controls (mean ± 
SD = 1.89 ± 2.21 %; p=0.0003 and 0.023, respectively). The levels of 
apoptotic lymphocytes seemed higher in SLE patients than in JRA  patients but 
the difference was statistically insignificant (p=0.58). There was no 
correlation between the  percentage of circulating apoptotic lymphocytes and 
the disease activity markers (SLEDAI and  ESR), different system involvement 
and the dose or duration of corticosteroids therapy.   
Conclusion: The general increase of circulating apoptotic lymphocytes seen in 
SLE patients may not be specific to SLE and could be seen with other 
autoimmune diseases. It seems that disturbance in the apoptotic process 
contributes more to the phenomenon of autoantigenicity rather than the 
prediction of the disease clinical activity or specific organ involvement. 
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neurodegeneration, autoimmunity, heart diseases 
and others 5. Increased in vitro apoptosis and altered 
expression of apoptosis-related molecules have 
been reported in systemic lupus erythematosus 
(SLE) 6.It was speculated that autoantigens released 
from apoptizing cells may contribute to the 
etiopathogenesis of SLE by both activation of 
autoreactive lymphocytes and the formation of 
immune complexes6. 
This work is aimed to study the apoptotic 
peripheral blood lymphocytes in patients with 
pediatric- onset SLE, to trace its correlations, if any, 
with the disease activity and clinical presentation, 
and to compare the apoptotic process to that in 




The study was conducted on 32 patients with 
pediatric-onset SLE (onset of the disease before 16 
years of age) recruited from those regularly 
attending the Pediatric Allergy and Immunology 
Outpatient Clinic, Children’s Hospital, Ain Shams 
University, Cairo. All of them fulfilled at least four 
of the American College of Rheumatology 
Classification criteria for SLE7.  They were twenty 
nine females (90.7%) and three males (9.3%); their 
age ranged between 5 and 25 years with a mean of 
15.5 ± 4.46 years. 
For comparison of our results, two groups were 
included:  
-Ten age and sex-matched patients with history of 
juvenile rheumatoid arthritis, eight females (80%) 
and two males (20%); their age ranged between 8 
and 17 years with a mean of 12.6 ±2.8 years.  
- Twenty age and sex-matched clinically healthy 
subjects; sixteen females (80%) and four males 
(20%); their age ranged between 8 and 23 years 
with a mean of 16± 3.8 years. 
Exclusion criteria: 
i- Infection till cured. 
ii- Active smoking 
All patients underwent the following: 
1- History taking including: 
• Age of onset and duration of the disease. 
• Presenting symptoms. 
• Different system involvement. 
• Therapeutic modalities. 
Patients received treatment according to the 
disease activity. Patients’ records of corticosteroids 
doses (prednisone or its equivalent in milligrams 
per kilograms body weight) were used to calculate 
the current dose and the duration of steroids therapy 
during the whole course of disease, and the duration 
of the last steroid regimen.  
 
Data for each patient were collected from: 
• Clinical and laboratory 
information recorded at 
the time of the study. 
• Medical records of the 
Pediatric Allergy and 
Immunology 
Outpatient Clinic. 
•  Personal interviews 
with each patient and 
parent (s) to obtain 
informations, e.g., 
events that were not 
available from the 
medical records. 
2- Clinical examination: 
• System involvements 
were sought for.  
• The disease activity 
was considered 
clinically according to 
SLEDAI 8, and the 
patients was 
considered to have low 
activity of SLE if 
SLEDAI was ≤ 15 and 
to have highly active 
disease if SLEDAI was 
> 15 9. 
3- The following laboratory investigations were 
done: 
a. CBC using coulter counter (T660, USA). 
b. ESR was determined by the Westergren 
method. 
c. Kidney function tests (serum creatinine and 
BUN) were determined by Synchron CX5 
Clinical System (Beckman, USA). 
d. Antinuclear antibodies (ANA) by immuno-
fluorescent microscopy (using commercially 
available slides coated with mouse kidney 
stomach tissue, obtained from Kallestad, 
Germany) and anti-native DNA antibodies 
(using commercially available slides coated 
with crithedia Luciliae substrate, obtained 
from Kallestad, Germany). 
e. Routine urine analysis (macroscopic and 
microscopic). 
f. Flowcytometric detection of apoptotic 
lymphocytes using fluorecein isothiocyanate- 
labeled Annexin –V.  
Principle of the assay: 
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Annexin V-FITC Apoptosis Detection Kit 
(Trevigen, Inc. RD Systems, Minneapolis, USA) 
uses Annexin V-FITC conjugates for 
flowcytometric detection of cell surface changes 
that occur early in the apoptotic process. The 
Annexin V-FITC conjugate facilitates rapid 
fluorimetric detection of apoptotic cells. Annexin V 
is an anticoagulant protein that preferentially binds 
negatively charged phospholipids. Early in the 
apoptotic process, phospholipids asymmetry is 
disrupted leading to the exposure of 
phosphatidylserine (PS) on the outer leaflet of the 
cytoplasmic membrane. This event is thought to be 
important for macrophage recognition of cells 
undergoing apoptosis 10. 
Different systems involvement: 
From the previous information collected as history, 
data records, examination, and investigations, organ 
involvement was determined according to the 
definitions provided by the American College of 
Rheumatology 11- 13.   
Statistical analysis:  
Data were analyzed with statistical software 
package v.5  (StatSoft, Tulsa, OK, USA). All 
numeric data were expressed as mean ± standard 
deviation (SD). Data were analyzed using student t-
test to compare mean values of different variables. 
Person r correlation coefficient was used to 
determine the relationship between different 
quantitative variables. Mann Whitney U test was 
used to compare non parametric data. For all tests, 




According to the report of the Second Task Force 
on Blood Pressure Control in Children (1987) 14, 24 
(75%) patients were considered hypertensive and 8 
patients were normotensive.  Renal involvement 
was encountered in the course of the disease in 14 
(43.75%) of our patients, 11 of whom had active 
renal disease during inclusion. Neuropsychiatric 
lupus was diagnosed in 40.6% of patients where 
manifestations varied between lupus headache, 
organic brain syndrome, seizures and psychosis. 
Nine (28%) of the studied patients had evidence of 
mucocutaneous involvement which included malar 
or discoid rash, mucosal ulcers and/or alopecia. On 
the other hand, nine patients were diagnosed as 
having secondary antiphospholipid antibody 
syndrome, where thrombotic evidence in the form 
of hemiparesis, deep venous thrombosis or 
myocardial infarction was associated with 
laboratory increased level of β2 glycoprotein- I 
antibody and / or Lupus anticoagulant (Table 1). 
Thirty patients have already received steroid 
therapy for a mean total duration of 25.4±14.05 
weeks. The current dosage ranged between 0.1 and 
1.8 mg/kg (mean 0.61 + 0.379 mg/kg) for a period 
ranging between 2 and 54 weeks (mean 11.74+13.2 
weeks). Four patients had received cytotoxic 
therapy; three of them received cyclophosphamide 
(700 mg/ m2 body surface area) and one received 
azathioprine (50 mg). 
The percentage of circulating early apoptotic 
lymphocytes was significantly higher in SLE 
patients (mean ± SD = 7.023±7.293 %, median = 
4.25%) and in JRA patients (mean ± SD = 
5.907±6.0008 %, median =3.24%) compared to 
healthy controls (mean ± SD = 1.878 ±2.207%, 
median =1.05%) [z=3.60 and 2.27,  p=0.0003 and 
0.023 respectively]. However, there was no 
significant difference in the percentage of apoptotic 
lymphocytes in SLE patients compared to JRA 
patients [z=-0.546, p=0.585] (Figure 1). The 
percentage of circulating early apoptotic 
lymphocytes was not significantly different in SLE 
patients with each system involvement (whether 
CNS, renal, mucocutaneous, antiphospholipid 
syndrome … etc.), compared to those without 
affection of that system. For instance, patients with 
active renal disease were comparable to those 
without nephropathy in terms of circulating early 
apoptotic lymphocyte percentage values. 
As to the effect of the disease activity on 
apoptosis, we found that the circulating early 
apoptotic lymphocytes were not significantly 
different in SLE patients with SLEDAI >15 
compared to those with low activity of the disease 
i.e. SLEDAI ≤15 (z= 0.226, p= 0.82), yet the values 
of both groups were higher than the healthy 
controls ( z= 2.98 and 3.108, p= 0.0028 and 0.008, 
respectively) (Figure 2). Furthermore, the levels of 
circulating early apoptotic lymphocytes were not 
significantly correlated to either the laboratory 
(ESR) or clinical (SLEDAI) markers of disease 
activity (Table 2).  
As to the effect of steroids therapy on the 
degree of apoptosis, the levels of circulating early 
apoptotic lymphocytes were not significantly 
correlated to either the dose or the duration of 









































Figure (1): Percentage values of circulating early 





































Figure (2): Comparison between SLE patients 
with SLEDAI >15 to those with SLEDAI ≤ 15 in 





Table (1): Descriptive clinical and laboratory 
data of SLE patients  
SLE patients 
(n= 32)  







- Lupus headache 
- Seizures 
- Organic brain syndrome 
- Psychosis 
13  (40%) 
8  (61.5%) 
2  (15.4%) 
4  (30.77%) 
1 (7.7%) 
• Active renal 
involvement 11 (34.38%) 




• Cardiac involvement: 5 (15.63%) 
- Pericardial effusion 
- Wall motion abnormality 








• ESR (mm/hr) 














Table (2): Correlation of the percentage of 
circulating early apoptotic lymphocytes to 
clinical and laboratory markers of activity in 
SLE patients  
Variable ESR SLEDAI 
Apoptotic 
lymphocytes %  
r = -0.30  
(p>0.05) 





Table (3): Correlation of the percentage of 
circulating early apoptotic lymphocytes to 














lymphocytes %  
r = -0.12 
(p>0.05) 
r = -0.03 
(p>0.05) 






The pathogenesis of most autoimmune diseases is 
unclear. Recently, much more attention has been 
devoted to the role of apoptosis in the pathogenesis 
of these diseases 15. The present study measured the 
levels of circulating early apoptotic lymphocytes in 
SLE patients compared to patients with JRA and to 
normal healthy controls. Experimental design with 
FITC-Annexin-V staining of freshly isolated 
lymphocytes was used to detect early apoptotic 
cells in circulation to avoid in vitro artifacts. 
Pediatric-onset SLE patients showed a 
significantly higher levels of circulating early 
apoptotic lymphocytes compared to normal healthy 
controls. Our results are in agreement with the 
study of Pernoik et al.9, and as well with the study 
of Courtney et al. 16, who found that the percentage 
of apoptotic lymphocytes was significantly 
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increased in the peripheral blood of SLE patients 
compared to normal healthy controls. Similar 
results were reported by Funauchi et al 17 and 
Grondal et al. 18, who studied early apoptosis in 
lymphocytes of SLE patients and found that the 
levels of apoptotic T lymphocytes were 
significantly increased compared to the healthy 
controls.   
To explain the relationship between SLE and 
the dysregulation of apoptosis, Emlen et al 19 and 
Lorenz et al 15 proposed that under physiologic 
conditions, cellular constituents are not released 
from apoptosis and therefore cannot activate 
immunocompetent cells. However, in theory, an 
increased rate of apoptosis could lead to an 
overflow of the phagocytic system with apoptotic 
cell bodies. Thus, intracellular constituents, such as 
apoptotic DNA fragments, would be presented to 
and recognized as non self antigens by 
immunocompetent cells leading to the formation of 
autoantibodies against intracellular particles such as 
ds-DNA. 
In agreement with the previous suggestion, are 
the results of the work of Casciola-Rosen et al 20, 
who reported that after ultra-violet (UV) irradiation-
induced in vitro apoptotic cell death of 
keratinocytes, most of the known SLE autoantigens 
are clustered within surface blebs of apoptotic cells. 
In another study, the same group found that after 
induction of apoptosis by Sindbis virus infection, 
viral antigens and autoantigens blebs form antigenic 
structure of mixed viral and self antigens and could 
define a novel immune context. Thus, an immune 
response originally directed against the virus could 
easily react with apoptotic particles. This could lead 
to formation of autoantibodies against intracellular 
constituents and initiation of autoimmune disease21. 
The increased amounts of circulating cells in 
the early phase of apoptotic cell death of SLE may 
be due to accelerated rate of apoptosis or defective 
clearance. It seems more likely that impaired 
clearance of apoptotic material contributes to the 
accumulation of apoptotic cells in SLE patients, as 
suggested by Herrmann et al 22, and Mevorach et al 
23. Defective clearance mechanisms may cause a 
flood of autoantigenic material from apoptotic 
bodies, leading to permanent challenge to natural 
tolerance. Opsonization of apoptotic material by 
autoantibodies and complement could then lead to 
antigenic spread of the inflammatory response 9. On 
the other hand, Gergely et al 24, in their study on 
peripheral blood lymphocytes from SLE patients, 
concluded that T cells are sensitized for apoptosis, 
which may significantly contribute to the increased 
spontaneous apoptosis. In contrast to our study 
results, the study done by Lorenz et al 15, and that 
by Bijl et al 6, failed to show significant difference 
in circulating apoptotic lymphocytes in the 
peripheral blood of SLE patients compared to 
healthy controls. 
This controversy may be explained by the 
difference in methodology and the selection of the 
patients  Lorenz et al., detected increased in vitro 
apoptosis, most likely reflecting apoptosis induced 
by non specific activation as characterized by 
increased Apo1/fas and Bcl2 expression. Analysis 
of apoptosis in vitro does not reflect the situation in 
living tissues as apoptotizing cells are usually 
cleared effectively in vivo by phagocytes 9. On the 
other hand, Bijl et al 6,  included in their study 
clinically quiescent SLE patients (SLEDAI score < 
4 for at least 4 months prior to blood sampling), on 
low dose corticosteroids with no immuno-
modulating drugs. 
A question needed to be addressed:, if these 
data were specific for SLE or can it also be seen in 
cells from patients with other autoimmune diseases. 
Comparing apoptotic lymphocytic cell counts from 
patients with SLE to those from patients with JRA, 
we found no significant difference  though both 
were significantly higher than values of the healthy 
control group. Similar results were reported by 
Courtney et al.16, who  found that the percentage of 
apoptotic lymphocytes and lymphocyte Fas 
expression in SLE were not significantly different 
from that of patients with rheumatoid arthritis, and 
concluded that increased lymphocytes apoptosis 
may not be specific to SLE.  
Furthermore, in their study, Lorenz et al. 15 
found that in vitro apoptosis and apoptosis-related 
molecules in lymophocytes from SLE patients were 
not significantly different from patients with other 
autoimmune diseases (e.g., mixed connective 
tissues disease, polyarteritis nodsa, Takayasu 
arteritis and Wegener's granulomatosis), and they 
concluded that the accelerated apoptosis represents 
a feature that is not specific for SLE, but can also 
be seen in autoimmune diseases characterized by a 
different pattern of autoantibodies. However, the 
same study showed that, the percentage of early 
apoptotic lymphocytes and apoptosis-related 
molecules from SLE patients were higher than that 
of rheumatoid arthritis (RA) patients. They 
proposed that T-cell migration in RA to the 
inflamed joints, which is not present in the 
peripheral vessels, might explain their findings. 
Their proposal was supported by Emlen et al. 19, 
and Nishimura- Morita et al. 25. It is also supported 
by Nakajima et al.26, who demonstrated typical 
apoptotic changes in rheumatoid arthritis synovial 
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cells in a significantly higher number than control. 
However, this was not the case in our study, where 
the levels of circulating apoptotic lymphocytes 
were not significantly increased in SLE compared 
to JRA patients. 
Concerning the correlation of circulating 
apoptotic cells with activity markers, whether 
clinical (SLEDAI) or laboratory (ESR), apoptotic 
cell counts revealed no significant correlation, and 
in a subgroup analysis of low active patients 
(SLEDAI ≤15) compared to highly active SLE 
patients (SLEDAI >15), there was no significant 
difference in circulating early apoptotic cells 
between the two SLE groups. In concordance to our 
results, Pernoik et al. 9, found no correlation 
between disease activity as measured by SLAM 
score, ESR, or ds-DNA antibody titer and 
apoptosis. Also, Grondal et al. 18, found no 
correlation between disease activity markers 
(SLEDAI and ESR) and apoptosis. The present 
study suggests that the activation-induced cell death 
may not be the only major factor in the high level of 
apoptotic cells. The subgroup analysis of low active 
patients with likewise elevated levels of early 
apoptotic cells implies a more generally disturbed 
removal of apoptotic material. By contrast, Emlen 
et al. 19 found only a weak positive correlation 
between clinical activity and the level of apoptosis 
in vitro culture. However, our experimental design 
of apoptosis detection in freshly isolated 
lymphocytes might better reflect in vivo conditions 
as the  afore-mentioned study was designed to 
record apoptosis under in vitro, non-inflammatory 
conditions and growth factor withdrawal. 
Focusing on results concerning correlation of 
circulating apoptotic cells with corticosteroids 
therapy, the total received dose of corticosteroids 
(in mg/kg), the total duration of corticosteroids 
therapy and the duration of current corticosteroids 
therapy showed no significant correlation to the 
level of apoptotic lymphocytes. Similarly,  Perniok 
et al.9, reported that apoptotic cell count revealed no 
correlation to corticosteroid doses, and concluded 
that the increase in apoptosis in SLE is independent 
on the therapeutic intervention. 
From former studies, data indicate that surface 
blebs of apoptotic cells constitute an important 
immunogenic particle in SLE. The phosphatidyl-
serine expressed on the outside of these blebs can 
induce the production of antiphospholipid 
antibodies. It was suggested that this could explain 
the increased incidence of pathological intravascular 
coagulation events that occur in some lupus patients 
who have antiphospholipid antibodies 21,27. 
Nevertheless, in our study, we found no significant 
difference in apoptotic cell count between patients 
with and without antiphospholipid antibody  
syndrome. 
In conclusion, the general increase of 
circulating apoptotic lymphocytes seen in SLE 
patients may not be specific to SLE and could be 
seen with other autoimmune diseases. It seems that 
disturbance in the apoptotic process contributes 
more to the phenomenon of autoantigenicity rather 
than the prediction of the disease clinical activity or 
specific organ involvement 
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